|1.26 0.28 (28.57%)||12-08 15:58|
|Targets||6-month :||1.84||1-year :||2.3|
|Resists||First :||1.58||Second :||1.97|
|Supports||First :||0.94||Second :||0.79|
|MAs||MA(5) :||1.03||MA(20) :||1.29|
|MA(100) :||1.95||MA(250) :||0|
|MACD||MACD :||-0.2||Signal :||-0.2|
|%K %D||K(14,3) :||18.2||D(3) :||7.6|
|52-week||High :||4.94||Low :||0.94|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AZTR ] has closed below upper band by 38.9%. Bollinger Bands are 8.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||1.27 - 1.28||1.28 - 1.28|
|Low:||1.01 - 1.01||1.01 - 1.02|
|Close:||1.25 - 1.26||1.26 - 1.27|
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Mon, 16 Oct 2023
Azitra to Present at the ThinkEquity Conference - Business Wire
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||0 (M)|
|Held by Insiders||0 (%)|
|Held by Institutions||0 (%)|
|Shares Short||0 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||0 %|
|Return on Equity (ttm)||0 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||0 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||0|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|